Atlanta/ Science, Tech & Medicine
AI Assisted Icon
Published on June 20, 2024
University of Georgia's Intranasal COVID-19 Vaccine CVXGA Set for Clinical Trials in FallSource: Unsplash/ Louis Reed

In a significant stride towards expanding the arsenal against COVID-19, the University of Georgia's latest development—an intranasal vaccine—is set to undergo clinical trials this fall. The vaccine, aptly named CVXGA, is the brainchild of CyanVac, a UGA-based start-up spearheaded by Dr. Biao He. CyanVac specializes in creating needle-free vaccines administered through the nasal passage.

According to FOX 5 Atlanta, the study will include 10,000 participants in a randomized, double-blind Phase 2b trial. Researchers aim to quickly assess how effective CyanVac's vaccine stands up in comparison to existing FDA-approved mRNA COVID-19 vaccines. Dr. Biao He, a driving force in vaccine innovation at UGA, has previously garnered recognition as UGA Inventor and Entrepreneur of the Year and contributed his expertise to a White House panel discussing the future trajectory of COVID-19 vaccines.

The technology harnessed in CVXGA, according to Dr. Biao He, leverages a modified strain of the parainfluenza virus 5, which typically affects dogs but is considered harmless to humans. "We are very excited about this opportunity to test a novel intranasal COVID vaccine whose technology platform has been developed at UGA," Dr. He expressed in a press release quoted by both FOX 5 Atlanta and The Red & Black.

The upcoming trials are sponsored through the U.S. Department of Health and Human Services' Project NextGen, a federal initiative designed to push forward cutting-edge vaccines and therapeutic treatments that could provide longer-lasting protection against COVID-19. A tribute to the university's unwavering support over the years, the vaccine's moniker—CVXGA—reflects the pride in UGA's contributions to this medical advancement. With its specific focus on intranasal delivery, the vaccine not only paves the way for an alternative to needle-based immunizations but also potentially offers practical advantages in distribution and administration.

Atlanta-Science, Tech & Medicine